Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease.

Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, Ngan B, Friesen C.

J Pediatr Gastroenterol Nutr. 2013 May;56(5):492-7. doi: 10.1097/MPG.0b013e3182801e60.

PMID:
23221994
2.

Elective switching from infliximab to adalimumab in stable Crohn's disease.

Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):761-6. doi: 10.1097/MIB.0b013e3182802ae1.

PMID:
23446337
3.

Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.

Furuta GT, Atkins D, Capocelli KE, de Zoeten EF, Fleischer D, Menard-Katcher C.

J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):e25. doi: 10.1097/MPG.0b013e3182a1e13b. No abstract available.

PMID:
23820407
4.

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Gisbert JP, Marín AC, McNicholl AG, Chaparro M.

Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4. Review.

5.

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.

Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P.

Inflamm Bowel Dis. 2011 Sep;17(9):1846-54. doi: 10.1002/ibd.21583. Epub 2011 Jan 6.

PMID:
21830263
6.

Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.

Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M.

Eur J Gastroenterol Hepatol. 2014 Apr;26(4):458-65. doi: 10.1097/MEG.0000000000000045.

PMID:
24445727
7.

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.

Inflamm Bowel Dis. 2014 Oct;20(10):1714-21. doi: 10.1097/MIB.0000000000000138.

PMID:
25069030
8.

Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.

Absah I, Faubion WA Jr.

Inflamm Bowel Dis. 2012 Aug;18(8):1488-92. doi: 10.1002/ibd.21885. Epub 2011 Aug 31.

PMID:
21882301
9.

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.

Am J Gastroenterol. 2014 Aug;109(8):1250-6. doi: 10.1038/ajg.2014.146. Epub 2014 Jun 10.

PMID:
24913041
10.

Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.

Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G.

Eur J Intern Med. 2014 Jun;25(5):485-90. doi: 10.1016/j.ejim.2014.02.010. Epub 2014 Mar 13.

PMID:
24631020
11.

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F.

J Rheumatol. 2013 Jan;40(1):74-9. doi: 10.3899/jrheum.120583. Epub 2012 Nov 1. Erratum in: J Rheumatol. 2013 Jan;40(1):106.

PMID:
23118110
12.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
13.

Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.

Patil SA, Rustgi A, Langenberg P, Cross RK.

Dig Dis Sci. 2013 Jan;58(1):209-15. doi: 10.1007/s10620-012-2323-0. Epub 2012 Sep 27.

PMID:
23014844
14.

Anti-TNF-alpha treatment strategies: results and clinical perspectives.

D'Haens G.

Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S209-16. doi: 10.1016/S0399-8320(09)73156-2.

15.

Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.

af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.

Scand J Gastroenterol. 2013 May;48(5):543-51. doi: 10.3109/00365521.2013.772230. Epub 2013 Mar 12.

PMID:
23477356
16.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.

Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Review. Erratum in: Am J Gastroenterol. 2011 Feb;106(2):375. Watermayer, G [corrected to Watermeyer, G].

PMID:
21045814
17.

Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.

Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M.

Scand J Gastroenterol. 2013 Aug;48(8):951-8. doi: 10.3109/00365521.2013.812141. Epub 2013 Jul 8.

PMID:
23834232
18.

Authors' response.

Turner D, Friesen C.

J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):e25-6. doi: 10.1097/MPG.0b013e3182a1df98. No abstract available.

PMID:
23820406
19.

Safety and efficacy of adalimumab in pediatric patients with Crohn disease.

Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L.

J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):19-25. doi: 10.1097/MPG.0b013e318174e886.

PMID:
18607264
20.

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.

Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.

Am J Gastroenterol. 2009 Dec;104(12):3042-9. doi: 10.1038/ajg.2009.493. Epub 2009 Sep 1.

PMID:
19724267

Supplemental Content

Support Center